(R)-3-amino-1,2,3,4-tetrahydrocarbazole is the important intermediate of synthesis Leimaquban. Leimaquban is efficient selectivity TXA2. (TXA2)/prostaglandin endoperoxide H 2 (PGH2) receptor antagonist, can be combined with smooth muscle and hematoblastic TXA2 receptor-specific. It has extremely strong blood vessel, bronchial smooth muscle contraction and platelet activation effect.
German Bayer company developed Ramatroban. It goes on the market in Japan first in 2001. It is efficient selectivity TxA2/PGH2 receptor antagonist, which can be combined with unstriated muscle and hematoblastic TxA2 receptor-specific for the treatment of allergic rhinitis.
And Ramatroban structural formula is (R)-3-amino-1,2,3,4-tetrahydrocarbazole and (S)-3-amino-1,2,3,4-tetrahydro carbazole is its a pair enantiomorph, wherein (R)-3-amino-1,2,3,4-tetrahydro carbazole is the key intermediate of synthesis Ramatroban bulk drug.
The anti-allergic effects of Leimaquban includes suppressing vascular permeability, nasal mucosa hyperreaction and preventing other inflammatory reaction from occurring. (R)-3-Amino-1,2,3,4-tetrahydrocarbazole is particularly well-suited to treatment allergic rhinitis.
